American Journal of Cardiology
Volume 90, Issue 10 , Pages 1107-1112 , 15 November 2002

Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA)

  • Karin Malmqvist, MD, PhD

      Affiliations

    • Division of Internal Medicine, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden
    • Corresponding Author InformationAddress for reprints: Karin Malmqvist, MD, PhD, Karolinska Institutet Danderyd Hospital, Section of Cardiology, Division of Internal Medicine, S-182 88 Stockholm, Sweden.
    • ,
  • Thomas Kahan, MD, PhD

      Affiliations

    • Division of Internal Medicine, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden
    • ,
  • Magnus Edner, MD, PhD

      Affiliations

    • Division of Internal Medicine, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden
    • ,
  • Lennart Bergfeldt, MD, PhD

      Affiliations

    • Department of Medicine, Unit of Cardiology, Karolinska Hospital, Karolinska Institutet, Stockholm, Sweden

Received 26 February 2002 ,Revised 19 July 2002 ,Accepted 19 July 2002.

References 

  1. Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J. 2001;141:334–341
  2. Messerli FH, Ventura HO, Elizardi DJ, Dunn FG, Frohlich ED. Hypertension and sudden death. Increased ventricular ectopic activity in left ventricular hypertrophy. Am J Med. 1984;77:18–22
  3. Messerli FH. Hypertension and sudden cardiac death. Am J Hypertens. 1999;12:181S–188S
  4. Aronson R. Mechanisms of arrhythmias in ventricular hypertrophy. J Cardiovasc Electrophysiol. 1991;2:249–261
  5. Hart G. Cellular electrophysiology in cardiac hypertrophy and failure. Cardiovasc Res. 1994;28:933–946
  6. Barr CS, Naas A, Freeman M, Lang CC, Struthers AD. QT dispersion and sudden unexpected death in chronic heart failure. Lancet. 1994;343:327–329
  7. Buja G, Miorelli M, Turrini P, Melacini P, Nava A. Comparison of QT dispersion in hypertrophic cardiomyopathy between patients with and without ventricular arrhythmias and sudden death. Am J Cardiol. 1993;72:973–976
  8. Perkiomäki JS, Huikuri HV, Koistinen JM, Makikallio T, Castellanos A, Myerburg RJ. Heart rate variability and dispersion of QT interval in patients with vulnerability to ventricular tachycardia and ventricular fibrillation after previous myocardial infarction. J Am Coll Cardiol. 1997;30:1331–1338
  9. Schmieder RE, Schlaich MP, Klingbeil AU, Martus P. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant. 1998;13:564–569
  10. Malmqvist K, Kahan T, Edner M, Held C, Hägg A, Lind L, et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens. 2001;19:1167–1176
  11. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, et al  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) (a randomised trial against atenolol). Lancet. 2002;359:995–1003
  12. Gonzalez-Juanatey JR, Garcia-Acuna JM, Pose A, Varela A, Calvo C, Cabezas-Cerrato J, et al. Reduction of QT and QTc dispersion during long-term treatment of systemic hypertension with enalapril. Am J Cardiol. 1998;81:170–174
  13. Karpanou EA, Vyssoulis GP, Psichogios A, Malakou C, Kyrozi EA, Cokkinos DV, et al. Regression of left ventricular hypertrophy results in improvement of QT dispersion in patients with hypertension. Am Heart J. 1998;136:765–768
  14. Lim PO, Nys M, Naas AA, Struthers AD, Osbakken M, MacDonald TM. Irbesartan reduces QT dispersion in hypertensive individuals. Hypertension. 1999;33:713–718
  15. Levy D, Salomon M, D’Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation. 1994;90:1786–1793
  16. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation. 1998;97:48–54
  17. van de Loo A, Arendts W, Hohnloser SH. Variability of QT dispersion measurements in the surface electrocardiogram in patients with acute myocardial infarction and in normal subjects. Am J Cardiol. 1994;74:1113–1118
  18. Lepeschkin ESB. The measurements of the Q-T interval of the electrocardiogram. Circulation. 1952;6:378–388
  19. Altman DG, Bland JM. Measurements in medicine: The analysis of comparison study. The Statiscians 1983;32:307–317
  20. Oikarinen L, Nieminen MS, Viitasalo M, Toivonen L, Wachtell K, Papademetriou V, et al. Relation of QT interval and QT dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients. The LIFE study. The Losartan Intervention For Endpoint Reduction. J Hypertens. 2001;19:1883–1891
  21. Perkiomäki JS, Ikaheimo MJ, Pikkujamsa SM, Rantala A, Lilja M, Kesaniemi YA, et al. Dispersion of the QT interval and autonomic modulation of heart rate in hypertensive men with and without left ventricular hypertrophy. Hypertension. 1996;28:16–21
  22. Clarkson PB, Naas AA, McMahon A, MacLeod C, Struthers AD, MacDonald TM. QT dispersion in essential hypertension. Quart J Med. 1995;88:327–332
  23. Gavras I, Gavras H. The antiarrhythmic potential of angiotensin II antagonism (experience with losartan). Am J Hypertens. 2000;13:512–517
  24. De Mello WC. Cardiac arrhythmias (the possible role of the renin-angiotensin system). J Mol Med. 2001;79:103–108
  25. Schwieler JH, Kahan T, Nussberger J, Hjemdahl P. Converting enzyme inhibition modulates sympathetic neurotransmission in vivo via multiple mechanisms. Am J Physiol. 1993;264:631–637
  26. Mazzolai L, Pedrazzini T, Nicoud F, Gabbiani G, Brunner HR, Nussberger J. Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice. Hypertension. 2000;35:985–991
  27. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation. 2000;102:1388–1393
  28. Varo N, Etayo JC, Zalba G, Beaumont J, Iraburu MJ, Montiel C, et al. Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats. J Hypertens. 1999;17:107–114
  29. Gimelli A, Schneider-Eicke J, Neglia D, Sambuceti G, Giorgetti A, Bigalli G, et al. Homogeneously reduced versus regionally impaired myocardial blood flow in hypertensive patients (two different patterns of myocardial perfusion associated with degree of hypertrophy). J Am Coll Cardiol. 1998;31:366–373
  30. Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA. 1998;279:1903–1907

☆ This study was supported by the Swedish Heart-Lung Foundation, Karolinska Institutet, Stockholm, Sweden; Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey; and Sanofi-Synthélabo, Paris, France.

PII: S0002-9149(02)02777-7

American Journal of Cardiology
Volume 90, Issue 10 , Pages 1107-1112 , 15 November 2002

Article Tools

* Image Usage & Resolution